The Impact on Method Performance When mAb Are Removed from a Spectral Immunophenotyping Panel

This study from Eurofins Viracor BioPharma evaluates the performance impact of reducing monoclonal antibodies (mAbs) in a spectral immunophenotyping panel by comparing a full 26-color panel with a condensed 13-color version. Both panels were validated using cryopreserved PBMCs from three donors on a BD FACSymphony A5 spectral flow cytometer. Results demonstrated strong intra-assay precision and high percent agreement (within 20%) between panels for all reportable populations. Despite reduced complexity, the 13-color panel maintained comparable resolution and reliability, supporting a fit-for-purpose approach for clinical testing where full panel breadth may not be necessary.